Motivation: The biological interpretation of differentially methylated sites derived from Epigenome-Wide-Association Studies (EWAS) remains a significant challenge. Gene Set Enrichment Analysis (GSEA) is a general tool to aid biological interpretation, yet its correct and unbiased implementation in the EWAS context is difficult due to the differential probe representation of Illumina Infinium DNA methylation beadchips. Results: We present a novel GSEA method, called ebGSEA, which ranks genes, not CpGs, according to the overall level of differential methylation, as assessed using all the probes mapping to the given gene. Applied on simulated and real EWAS data, we show how ebGSEA may exhibit higher sensitivity and specificity than the current state-of-the-art, whilst also avoiding differential probe representation bias. Thus, ebGSEA will be a useful additional tool to aid the interpretation of EWAS data. Availability and implementation: ebGSEA is available from https://github.com/aet21/ebGSEA, and has been incorporated into the ChAMP Bioconductor package (https://www.bioconductor.org).
Introduction
The number of Epigenome-Wide-Association Studies (EWAS) has grown rapidly, yet the biological interpretation of the differentially methylated sites found in these studies remains a significant problem (Lappalainen and Greally, 2017; Teschendorff and Relton, 2018) . EWAS typically use Illumina Infinium beadchips to measure DNA methylation (DNAm) at over 480 000 or 850 000 CpGs, depending on the beadchip version (Beck, 2010; Moran et al., 2016) , and genes represented on these chips may have widely different numbers of probes mapping to them (Phipson et al., 2016) . It has been noted that this differential probe representation may cause significant bias when conducting differential methylation and Gene Set Enrichment Analysis (GSEA), favouring genes with more probes (Geeleher et al., 2013; Phipson et al., 2016) . This is similar to the well-known bias of RNA-Seq differential expression calls towards longer genes, and for this reason, methods that adjust for this bias in RNA-Seq data have been adapted to the DNAm context (Phipson et al., 2016) . However, drawing an analogy between RNA-Seq and DNAm data is also misleading, because in the RNA-Seq context the length of the gene only affects the reliability of the measured expression level, whereas in the DNAm context, the reliability of the measured DNAm level at a given CpG site does not depend on the number of probes mapping to the same gene. Thus, although genes with higher probe representation are more likely to be called differentially methylated, directly adapting methods from RNA-Seq data to DNAm beadchips may introduce other biases and still lead to suboptimal GSEA.
Description
Here we present a novel GSEA method for Illumina DNAm data, with an empirical Bayes interpretation (thus called ebGSEA), which overcomes the differential probe representation bias, whilst also avoiding some of the residual biases of current state-of-theart methods like GSAmeth (Phipson et al., 2016) . GSAmeth works by ranking differentially methylated CpGs (DMCs), selecting those that pass a genome-wide significance threshold, then mapping these to genes and finally to biological terms (pathways). Adjustment for differential probe representation is carried out at the gene-mapping stage, whereby the significance of the number of DMCs mapping to a given gene is assessed in relation to how many probes map to that gene. This, however, may result in two undesirable outcomes. First, genes in a pathway where a substantial fraction of marginal DMCs do not pass genome-wide significance levels may result in the enrichment of the pathway being missed ( Fig. 1a-d, Supplementary Material) . Second, two pathways, matched for all variables (number of genes, probes mapping to each gene, number of genes containing at least one DMC) but differing widely in terms of the number or effect size of DMCs within a gene, will be ranked equally (Supplementary Material). ebGSEA overcomes these problems by adapting the global test (Goeman et al., 2004) to directly rank genes according to their overall level of differential methylation, as assessed using all of the probes that map to the given gene and in a manner which avoids favouring genes containing more probes. Subsequently, enrichment of biological terms is performed on this ranked list of genes using either a standard one-tailed Wilcoxon rank sum test, or a recently introduced more powerful version known as the Known Population Median test (Parks, 2018) . As a result, in the first scenario considered above, affected genes will be relatively highly ranked via ebGSEA (Fig. 1c) , and the ensuing ranked list leads to significant enrichment of the pathway (Fig. 1d ). In the second scenario, ebGSEA will favour the pathway containing more DMCs, as required (Supplementary Material).
We also compared ebGSEA to GSAmeth in a smoking-EWAS performed on 400 buccal swabs (Teschendorff et al., 2015) . Here, ebGSEA ranked a biological term associated with smoking-related head&neck cancer much more highly than GSAmeth, the latter exhibiting wide variation depending on the number of top-ranked DMCs (Fig. 1e, Supplementary Material) . For instance, selecting the top-500 DMCs, GSAmeth would not have ranked this smokingrelated term among the top-25% enriched ones, in contrast to ebGSEA which ranked it among the top 1% ( Fig. 1e ). Of note, the ranking or statistical significance of genes derived from ebGSEA did not correlate with the number of CpGs mapping to the gene, confirming that ebGSEA, like GSAmeth, avoids differential probe representation bias (Fig. 1f) . Similar results were observed in other EWAS ( Fig. 1g-i, Supplementary Material) .
Conclusion
We propose that ebGSEA be used alongside other GSEA methods to obtain a more objective and comprehensive assessment of GSEA in a given EWAS. (f) Significance of the genes, as given by ebGSEA, versus the number of CpGs mapping to the gene, as derived using ebGSEA in the same smoking-EWAS. R 2 value demonstrates that ebGSEA is unbiased. (g-h) As (e-f), but now for a term of transcriptionally altered genes in an age-EWAS performed in blood. (i) As panels f and h, but now for rheumatoid arthritis in an EWAS performed in blood
